Diabetes mellitus is associated with an increased risk of thrombosis, circulatory dysfunction and atherosclerosis. Attenuated endothelium-dependent relaxation [1], altered smooth muscle contractility [2] and enhanced reagibility of platelets [3, 4, 5] are thought to constitute the main promoters for vascular complications and atherogenesis in diabetes mellitus. Although increased aggregation of platelets isolated from diabetic patients to autacoids, such as ADP or thrombin, has been clearly shown [6] , the molecular mechanism of this hyperreactivity of the thrombocytes is still not clear.
Summary Increased aggregation of platelets might contribute to the development of vascular complication in diabetes mellitus. In this study release of superoxide anions, intracellular Ca 2+ signalling and nitric oxide formation stimulated by the receptor-dependent agonist adenosine 5 ¢-diphosphate (ADP) and the receptor-independent stimulus thapsigargin, were compared in platelets isolated from patients with Type II (non-insulin-dependent) diabetes mellitus and healthy control subjects. Diabetes augmented intracellular Ca 2+ release and Ca 2+ entry to ADP by 40 and 44 % (control subjects: n = 11; diabetic: n = 6), while the median effective concentration (EC 50 ) of ADP to initiate Ca 2+ signalling was similar in both groups. The effect of thapsigargin on Ca 2+ concentration was increased by 69 % in diabetic patients (control subjects: n = 22; diabetic patients: n = 9). In addition, release of superoxide anions was 70 % greater in diabetic patients (control subjects: n = 9; diabetic patients: n = 6). Treatment of platelets from control subjects with the superoxide anion-generating mixture xanthine oxidase and hypoxanthine or buthioninesulphoximine (BSO) mimicked the effect of diabetes on platelet Ca 2+ signalling. The antioxidant glutathione normalized enhanced Ca 2+ response in the diabetic group (control subjects: n = 5; diabetic patients: n = 6). Basal and thapsigarginevoked nitric oxide synthase activity was reduced in the diabetic group by 85 and 64 %, respectively (control subjects: n = 13; diabetic subjects: n = 13). The nitric oxide-donor 2-(N,N-diethylamino)-diazenolate-2-oxide sodium (DEA/NO) normalized enhanced Ca 2+ signalling in platelets preincubated with xanthine oxidase and hypoxanthine (n = 12) and in those from diabetics (control subjects: n = 6; diabetic patients: n = 6). Inhibition of nitric oxide synthase by N-nitro-L-arginine (L-NA) augmented thapsigargininduced Ca 2+ signalling by 51 % (n = 8). These data indicate that in diabetes platelet Ca 2+ signalling might be enhanced by excessive superoxide production and an attenuated negative direct or indirect feedback control by nitric oxide, due to its reduced production. [Diabetologia (1999) 42: 167±176] tion of phospholipase C-mediated synthesis of diacylglycerol and inositol 1,4,5-trisphosphate (IP 3 ). The latter evokes intracellular Ca 2+ release from the endoplasmic reticulum Ca 2+ stores [7] . In addition, the depletion of intracellular Ca 2+ stores initiates activation of a so called capacitative Ca 2+ entry [7, 8] . Both, intracellular Ca 2+ release and capacitative Ca 2+ entry increase free intracellular Ca 2+ concentration [Ca 2+ ]; and induce platelet aggregation by stimulation of the thromboxane A 2 biosynthesis [9] . In platelets from diabetic patients, increased intracellular Ca 2+ response was reported [10] . So far no detailed analysis of diabetes-mediated changes in platelet Ca 2+ signalling was conducted and the biochemical mechanisms of this increased platelet Ca 2+ mobilization are not clear. On the other hand, an increase in [Ca 2+ ]; might favor the biosynthesis of nitric oxide by the Ca 2+ -sensitive, constitutive platelet nitric oxide synthase [11] . Nitric oxide has been shown to increase platelet cGMP concentrations by stimulation of soluble guanylyl cyclase [12, 13] resulting in several intracellular reactions such as activation of protein kinases and lowering of basal intracellular Ca 2+ [14] and in an attenuation of platelet aggregation [15] . Remarkably, basal nitric oxide synthase activity in homogenates of platelets obtained from diabetic patients is reduced [16] while differences in the stimulation of nitric oxide synthase activity upon autacoid stimulation has not been investigated so far. Besides its effect on the platelet signalling pathways mentioned above, diabetes is associated with increased hydrogen peroxide production in platelets from diabetic patients [17, 18] . Recently, increased production of superoxide anions has been described to contribute to changes in endothelial function under hyperglycaemic conditions [19, 20] . So far limited information is provided about increasing formation of superoxide anions in platelets in diabetes and, if so, to which extent the increased production of superoxide anions contributes to the observed changes of platelet functions.
Thus, there are many studies reporting diabetesinduced changes in platelet function but the intracellular mechanisms and the role of reactive oxygen species in the reported changes of platelet function in diabetes are still unclear. The aim of our study was to assess the effect of diabetes on platelet signal transduction in more detail and to correlate the observed alterations with increased free radical formation. To investigate the effect of diabetes on receptor-mediated Ca 2+ signalling, the effects of the receptor-dependent agonist ADP were tested. In addition, the effect of diabetes on platelet capacitative Ca 2+ entry was exclusively tested using the Ca 2+ ATPase inhibitor which activates Ca 2+ entry by Ca 2+ store depletion independently of any receptors or second messengers. We also investigated the effect of glutathione, a powerful antioxidant on diabetes-induced changes of platelet Ca 2+ signalling to verify whether prevention of free radical release might have an impact on diabetes-modified signal transduction in platelets.
Materials and methods
Subjects. In this study, cell activity to autacoid stimulation was assessed in platelets isolated from 33 healthy subjects and 30 Type II (non-insulin-dependent) diabetic patients recruited from a diabetes outpatient clinic. Type II diabetes was diagnosed in all patients according the clinical NDDG (national diabetes data group) criteria [21] . All subjects entered the study voluntarily and gave informed consent. To be eligible, diabetic patients had to be normotensive and free of clinical overt macrovascular disease. Retinopathy exceeding microaneurysms (severity level 21) as well as macroalbuminuria were also exclusion criteria. Antihyperglycaemic treatment in the diabetic group was either by diet alone or by premixed insulin twice daily and patients did not receive any other long-term drug treatment. As shown in Table 1 , groups differed only in terms of blood D-glucose concentration and HbA 1 c . Blood was collected from all subjects in the morning after an overnight fast. Clinical laboratory parameters were measured by routine laboratory methods.
Materials. Fura-2 acetoxymethylester was purchased from Lambda Fluorescence Technologies (Graz, Austria). 2-(N,Ndiethylamino)-diazenolate-2-oxide sodium (DEA/NO) was purchased from Alexis (Läufelfingen, Switzerland). Buffer salts were obtained from Merck (Darmstadt, Germany). The 
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2+ measurements. Intracellular Ca 2+ concentration was measured using conventional fluorescence spectroscopy with fura-2 acetoxymethylester as described previously [23] . Briefly, the platelets suspended in buffer A were incubated for 45 min at room temperature with 2 mmol/l fura-2 acetoxymethylester, washed twice and resuspended in buffer A. Intracellular free Ca 2+ concentration was monitored in a stirred spectrofluorometer by measuring fluorescence at 340 and 380 nm excitation and 510 nm emission. Due to the reported errors in the calibration of the intracellular Ca 2+ concentration, free intracellular Ca 2+ concentration is expressed as ratio units of 340/380 nm excitation and 510 nm emission. To demonstrate the accuracy of the presentation of intracellular Ca 2+ concentration as ratio units (F 340 /F 380 ), Ca 2+ signalling was regularly calibrated using the technique as described by Grynkiewicz et al. [24] .
Measurement of platelet nitric oxide synthase activity. Activity of platelet nitric oxide synthase was determined by measuring the conversion of [ After 15 min incubation under constant stirring at room temperature, the reaction was stopped by addition of 1 ml chilled buffer A, washed and centrifuged with 900´g for 5 min at 4°C. The platelet pellet was lysed with 1.00 ml 0.01 mol/l HCl. After 30 min at 4°C, radioactivity of a 100 ml aliquot was determined using liquid scintillation counting for calculation of the incorporated radioactivity (R*) during experimental conditions (R* = dpm´10). To the remaining sample, 100 ml of a 200 mmol/l sodium acetate buffer (pH 13.0) containing 10 mmol/l L-citrulline was added. To separate the amino acids, 900 ml of this solution (final pH 5.0±5.2) was applied to ion exchange resin columns (7 ml; AG 50W-X8, 400 mesh, H + form). The Determination of superoxide anion release. Release of superoxide anions was determined photometrically as the superoxide dismutase (SOD)-inhibitable reduction of ferricytochrome c as previously described [19, 20] . Briefly, platelets were adjusted in buffer A to 10 8 cells/ml in the absence or presence of 200 U/ml SOD and transferred into a stirred 6-fold holder (3 for each with and without SOD) in a photometer, Hitachi U-2000 (Inula, Vienna, Austria). After addition of 10 mmol/l ferricytochrome c release of superoxide anions were monitored at 550 nm for 60 min. The difference of extinction between samples in the absence and presence of SOD indicate superoxide anion-mediated reduction of ferricytochrome c. Concentration of superoxide anions was calculated using the molar extinction coefficient of reduced form of ferricytochrome c (e = 21.000; [25] ).
Experimental generation of superoxide anions. For the exposure of platelets to experimentally produced superoxide anions, platelets were treated for 1 h in buffer A containing 300 mU/ml xanthine oxidase and 1 mmol/l hypoxanthine at room temperature as described previously [26] .
Statistical analysis. Experiments for each subject were done in triplicate and given ªnº values representing the number of patients or healthy control subjects of this study. Data points represent the means ± SEM. The EC 50 values are expressed as the mean with 95 % confidential intervals in parenthesis. Analysis of variance (ANOVA) was used for data evaluation and statistical significance of differences between means was estimated by Scheffe's F-test. The level of significance was defined as p < 0.05.
Results
Comparison of cell size and volume of platelets. Distribution of cell size, mean diameter and cell volume of the platelets was measured in diabetic patients and healthy control subjects. There was no difference in cell size (control subjects: 2.77 ± 0.23 mm, n = 10; diabetic patients: 2.78 ± 0.22 mm, n = 10) and cell volume (control subjects: 13.86 ± 0.70 fl, n = 10; diabetic patients: 13.49 ± 0.81 fl, n = 10) between both groups.
Diabetes-related differences in platelet Ca 2+ signalling to autacoid stimulation. Intracellular Ca 2+ response to ADP stimulation was investigated in fura-2 loaded platelets isolated from diabetic and healthy subjects. Platelets were stimulated in nominal Ca 2+ free solution (no Ca 2+ added) with the ADP concentration indicated, followed by the addition of 2.5 mmol/l Ca 2+ . The intracellular Ca 2+ release upon 100 mmol/l ADP was increased by 44 % in platelets isolated from diabetic patients compared with that in platelets from control subjects ( Fig. 1A; control subjects: n = 11; diabetic patients: n = 6). Hence, the increase of intracellular Ca 2+ concentration to the addition of 2.5 mmol/l Ca 2+ to ADP stimulated cells was 40 % greater than in control platelets (Fig. 1A) . Figure 1B summarizes the effect of various ADP concentrations on intracellular Ca 2+ concentration in platelets from diabetic and control subjects (control: n = 11; diabetic: n = 6). While increases in intracellular Ca 2+ concentration in response to ADP higher than 10 mmol/l were greater in platelets of diabetic patients compared with those measured in platelets from healthy subjects, EC 50 values for ADP remained unchanged in both groups (control group: 10.32 (5.3±20.1) mmol/l; diabetic group: 8.02 (2.7±23.9) mmol/l/).
In addition to the enhanced Ca 2+ signalling in response to the IP 3 -generating autacoid ADP, increases in free intracellular Ca 2+ concentration to the ATPase inhibitor thapsigargin were also found to be enhanced by 67 % in platelets derived from diabetic patients compared with those obtained in platelets from the control group ( Fig. 2; control subjects: n = 22; diabetic group: n = 9).
Nitric oxide synthase activity. 2+ signalling evoked by 1 mmol/l thapsigargin in the presence of 2.5 mmol/l extracellular Ca 2+ in freshly isolated washed platelets were loaded with fura-2/am for 45 min. Points indicate the means ± SEM (control subjects: k, n = 22; diabetic subjects: U, n = 9). *p < 0.05 vs effect in platelets from healthy control subjects Thapsigargin * * Fig. 3 . Diabetes mellitus effects nitric oxide synthase activity in human platelets. In freshly isolated and washed platelets from diabetic and healthy subjects, activity of nitric oxide synthase under basal condition and during stimulation with 1 mmol/l thapsigargin was measured. Each column represents the mean ± SEM (control subjects: open columns, n = 13; diabetic patients: filled columns, n = 13). *p < 0.05 vs effect in platelets from healthy control subjects . Points indicate the means ± SEM (control subjects: k, n = 11; diabetic subjects: U, n = 6). *p < 0.05 vs effect in platelets from healthy control subjects. B Intracellular rises in free Ca 2+ concentration in the nominal absence of extracellular Ca 2+ concentration (i. e. intracellular Ca 2+ release) to the ADP concentrations indicated. Identical results were obtained for the increases in the intracellular Ca 2+ concentration to the addition of extracellular Ca 2+ to ADP stimulated cells. Data represent the means ± SEM (control subjects: k, n = 11; diabetic subjects: U, n = 6). *p < 0.05 vs effect in platelets from healthy control subjects basal conditions and on stimulation with autacoids. In platelets from diabetic patients, basal nitric oxide synthase activity was 15 % of that measured in the control subjects ( Fig. 3 ; control: n = 13; diabetic n = 13). In addition, the effect of 1 mmol/l thapsigargin nitric oxide synthase activity was reduced by 64 % in platelets from diabetic patients compared with that measured in platelets of non-diabetic subjects ( Fig. 3 ; control: n = 13; diabetic: n = 13).
In contrast to the large difference in nitric oxide synthase activity in both basal and stimulated conditions, there was no difference in the uptake of the nitric oxide synthase substrate L-arginine between platelets isolated from diabetic patients or healthy control subjects (control: 15.79 ± 1.81 dpm´10 3 /10 8 cells´15 min, n = 13; diabetic: 19.6 ± 0.99 dpm1 0 3 /10 8 cells´15 min, n = 13, NS compared with control subjects, control: n = 13; diabetic: n = 13).
Superoxide anion release. To verify whether under diabetic conditions, increased superoxide anion formation occurs in human platelets, the release of superoxide anions from platelets donated from diabetic and healthy subjects was compared. In platelets from diabetic subjects, release of superoxide anions was increased by 70 % compared with that measured in platelets from healthy subjects ( Fig. 4A ; control: n = 9; diabetic: n = 9). Incubation of platelets with 10 mmol/l glutathione for 45 min at room temperature strongly reduced superoxide anion release in both groups, while no further difference between platelets derived from diabetic and non-diabetic subjects was found ( Fig. 4B ; control: n = 5; diabetic: n = 6).
Effect of superoxide production on platelet Ca 2+ signalling. To elucidate the contribution of the increased superoxide anion production and release found in platelets from diabetic patients to the observed hyperreactivity of the Ca 2+ signalling to agonists, platelets isolated from healthy subjects were incubated for 60 min in buffer A containing 300 mU/ml xanthine oxidase and 1 mmol/l hypoxanthine. Treatment of platelets with the superoxide anion-generating sys- . Points represent the means ± SEM. *p < 0.05 vs the effect in non-treated platelets (n = 5 for each group). B Platelets were stimulated in the presence of 2.5 mmol/l extracellular Ca 2+ with 1 mmol/l thapsigargin for 3 min. Columns represent the maximum increase in intracellular Ca 2+ concentration in response to thapsigargin. *p < 0.05 vs the effect in non-treated platelets (n = 9 for each group) tem increased ADP-induced Ca 2+ response by 55 and 73 % (intracellular Ca 2+ release and Ca 2+ entry, respectively ( Fig. 5A ; n = 5)). In agreement with these findings treatment of platelets with 300 mU/ml xanthine oxidase in the presence of 1 mmol/l hypoxanthine increased thapsigargin induced elevation of intracellular Ca 2+ concentration in Ca 2+ containing solution by 55 % (Fig. 5B ; n = 9).
Preincubation of platelets isolated from healthy subjects with 10 mmol/l L-lactate for 2 h at room temperature mimicked the effect of xanthine oxidase and diabetes on platelet Ca 2+ signalling ( Fig. 6A ; n = 6). Like the effect of ADP, thapsigargin-evoked (1 mmol/l) increase in free intracellular Ca 2+ concentration in the presence of 2.5 mmol/l extracellular Ca 2+ was increased by 90 % in cells pretreated with 10 mmol/l L-lactate ( Fig. 6B ; n = 7).
Lowering glutathione content on the platelets by incubation with 5 mmol/l buthioninesulphoximine (BSO) for 2 h increased the release of superoxide anions from platelets by 137 % (Fig. 7A ; n = 6) and mimicked the effect of diabetes on platelet Ca 2+ signalling in response to 100 mmol/l ADP ( Fig. 7B; n = 6 ).
Effect of glutathione on diabetes-induced changes in platelet Ca
2+ signalling. Preincubation of platelets from diabetic patients with 10 mmol/l glutathione for 1 h before the experiment normalized platelet Ca 2+ signalling to ADP, while treatment of platelets of healthy subjects with glutathione did not influence the ADP-induced Ca 2+ signalling ( Fig. 8A ; control subjects: n = 6; diabetic subjects: n = 6). Figure 8B summarizes the effect of the pretreatment with glutathione on the effectiveness of various ADP concentrations to initiate changes in intracellular Ca 2+ concentration in platelets from diabetic and healthy persons. The glutathione treatment normalized Ca 2+ signalling in platelets from diabetic patients in all concentrations, while EC 50 values for ADP remained unchanged in both groups after treatment with glutathione (control subjects: 3.3 (0.8±14.0) mmol/l; diabetic subjects: 3.8 (1.0±14.7) mmol/l). In agreement with these findings glutathione normalized enhanced thapsigargin-induced Ca 2+ increases in platelets isolated from diabetic persons ( Fig. 8C ; control: n = 10; diabetic: n = 10). Effect of nitric oxide on superoxide anion-evoked changes in platelet Ca 2+ signalling. Preincubation of platelets with the nitric oxide donor DEA/NO (1 mmol/l; [27] ) for 5 min before stimulation with 100 mmol/l ADP diminished intracellular Ca 2+ release and capacitative Ca 2+ entry by about 20 and 28 %, respectively (Fig. 9A) . Moreover, a 5 min incubation period with the NO donor DEA/NO (1 mmol/l) normalized ADP-induced Ca 2+ signalling in platelets pretreated for 1 h with 300 mU/ml xanthine oxidase in the presence of 1 mmol/l hypoxanthine ( Fig. 9A ; n = 12). Also a 5 min incubation with the NO donor DEA/NO (1 mmol/l) normalized ADP-induced Ca 2+ signalling in platelets isolated from diabetic patients ( Fig. 9B; n = 6 ). signalling in platelets isolated from diabetic patients. Freshly isolated washed platelets from healthy subjects (k, A) diabetic patients (U, R) were preincubated for 45 min in the absence (k, U) or presence (A, R) of 10 mmol/l glutathione at room temperature. A Representative tracings of the effect of 100 mmol/l ADP on Ca 2+ concentration in platelets isolated from diabetic and non-diabetic subjects. As bars indicate cells were stimulated in the absence of extracellular Ca 2+ with 100 mmol/l ADP followed by the addition of 2.5 mmol/l Ca 2+ . Points indicate the means ± SEM. *p < 0.05 vs non-diabetic control subjects and # p < 0.05 vs the response without treatment with glutathione (control subjects: n = 5; diabetic subjects: n = 6). B Intracellular rises in free Ca 2+ concentration in the nominal absence of extracellular Ca 2+ concentration to the ADP concentrations indicated in platelets from control subjects and diabetic patients without and with an incubation for 45 min with 10 mmol/l glutathione at room temperature. *p < 0.05 vs non-diabetic control subjects and # p < 0.05 vs the response without treatment with glutathione (control subjects: n = 5; diabetic patients: n = 6). C Platelets were stimulated in the presence of 2.5 mmol/l extracellular Ca 2+ with 1 mmol/l thapsigargin for 3 min. Columns represent the maximal increase in intracellular Ca 2+ concentration in response to thapsigargin in platelets from control subjects (open columns) and diabetic patients (filled columns). *p < 0.05 vs control subjects (n = 10 for each group) Fig. 9 A, B. Effect of nitric oxide on ADP-induced Ca 2+ signalling in platelets without and with preincubation with xanthine oxidase/hypoxanthine (A) and on platelets isolated from control and diabetic patients (B). A Freshly isolated washed platelets from healthy individuals were incubated for 1 h in buffer A without (k, A) and with (U, R) 300 mU/ml xanthine oxidase and 1 mmol/l hypoxanthine. Before the experiments, cells were washed twice and incubated for 5 min without (k, U) or with (A, R) 1 mmol/l DEA/NO, washed and resuspended in nominal Ca 2+ free buffer A. As bars indicate platelets were stimulated in the nominal absence of extracellular Ca 2+ with 100 mmol/l ADP followed by the addition of 2.5 mmol/l Ca 2+ . Points represent the mean ± SEM (n = 12 each group). *p < 0.05 vs control subjects and # p < 0.05 vs HX/XO + NO. B Freshly isolated platelets from control subjects (k, A) and diabetic subjects (U, R) were incubated in buffer A for 5 min without (k, U) or with (A, R) 1 mmol/l DEA/NO, washed and resuspended in nominal Ca 2+ free buffer A. As bars indicate platelets were stimulated in the nominal absence of extracellular Ca 2+ with 100 mmol/l ADP followed by the addition of 2.5 mmol/l Ca 2+ . Points represent the means ± SEM (n = 6 each group). *p < 0.05 vs control subjects and # p < 0.05 vs diabetic group
Inhibition of platelet nitric oxide synthase by 1 mmol/l L-NA augmented platelet Ca 2+ signalling in response to 1 mmol/l thapsigargin ( Fig. 10 ; control: n = 8 in each group), while the effect of ADP (100 mmol/l) was not changed in the presence of L-NA (data not shown).
Discussion
We studied diabetes-induced changes in autacoid-induced Ca 2+ signalling and nitric oxide biosynthesis in human platelets. In addition release of superoxide anions from platelets isolated from diabetic patients was compared with that measured in platelets from healthy subjects. We provided evidence that in diabetes increased superoxide anion production in platelets occurs, resulting in an increase in agonist-induced intracellular Ca 2+ signalling. Moreover, basal and thapsigargin-stimulated nitric oxide synthase was greatly reduced in platelets from diabetic patients. This might result in an attenuation of the nitric oxide-mediated direct or indirect negative feedback for Ca 2+ signalling. Our data suggest that platelet hyperreactivity in diabetes is, at least in part, due to an increased autacoid-induced intracellular Ca 2+ signalling because of increased superoxide anion formation and reduced nitric oxide synthase activity.
Increased platelet aggregation in diabetes is thought to be due to increased cellular responsiveness of thrombocyte signal transduction for aggregation, associated with attenuated compensatory mechanisms (e. g. nitric oxide formation). In this study, intracellular Ca 2+ signalling as main regulator to autacoid-induced aggregation is shown to be increased in platelets from diabetic patients. These findings are consistent with a report that showed enhanced autacoid-induced Ca 2+ responses in platelets from diabetic subjects [10] . Our data clearly indicate enhanced intracellular Ca 2+ release to the IP 3 -generating agonist ADP. There is an enhancement of inositolphosphate formation to thrombin in platelets from diabetic patients [28] . In spite of the enhanced intracellular Ca 2+ signalling in response to ADP, the EC 50 values in the diabetic and the control group were similar. These data suggest that the observed enhancement in platelet Ca 2+ signalling in response to ADP in diabetic patients is not caused by an increased sensitivity of the P2Y1 receptor to ADP [29] . In platelets, Ca 2+ entry follows activation of a so-called capacitative Ca 2+ entry. The activity of this Ca 2+ influx pathway correlates with the depletion of intracellular Ca 2+ stores by way of IP 3 [7] . The increase in Ca 2+ entry in platelets of diabetic patients might be caused by intracellular Ca 2+ store depletion in response to a given ADP concentration and is more pronounced in platelets from diabetic persons. Since Ca 2+ entry activated by thapsigargin, which depletes all Ca 2+ stores by inhibition of endoplasmic reticulum Ca 2+ ATPases [30] , was also enhanced in platelets from diabetic patients, a direct effect of diabetes on Ca 2+ entry pathway is suggested.
The effect of diabetes on the intracellular Ca 2+ response to ADP was mimicked by preincubation of platelets with the superoxide anions-generating mixture xanthine oxidase/hypoxanthine and an induction of intracellular superoxide anion production by an inhibition of intracellular glutathione synthesis with BSO [19] . Since we could show that in platelets from diabetic patients, superoxide anion release is greater than that obtained in platelets from healthy subjects, these data might indicate that increased Ca 2+ signalling of platelets in diabetes is caused by the enhanced production and release of superoxide anions. This hypothesis is also confirmed by our findings that preincubation of platelets with L-lactate, which increased platelet intrinsic superoxide anion formation, mimicked the effect of diabetes on platelets Ca 2+ signalling pathways. L-lactate has been demonstrated to mimic the effect of diabetes on blood flow by inducing radical changes of NAD + /NADH + ratio, which might result in an overproduction of superoxide anions [31] . Hence, in endothelial cells hyperglycaemia-induced changes in Ca 2+ signal transduction pathways, which are quite similar to those in platelets [7] , were recently shown to be caused by enhanced superoxide anion production by D-glucose autoxidation [19] . Consistent with the similarities between the changes of endothelial and platelet responsiveness and the potential role of superoxide anions to constitute the trigger for the alterations in the Ca 2+ signalling, the antioxidant glutathione normalized the enhanced Ca 2+ signalling in platelets isolated from diabetic patients (this study) and that of endothelial cells during hyperglycaemia [32] . These data clearly indicate similarities in changes in platelet and endothelial cell Ca 2+ signalling during diabetes and hyperglycaemia, which might be due to the great similarities in the Ca 2+ controlling mechanisms in both cell types. In platelets, however, basal and autacoid-stimulated formation of nitric oxide was markedly reduced by diabetes while in endothelial cells controversial findings have been made [33, 34] . The reduced basal nitric oxide formation in intact platelets during diabetes found in our study are consistent with previous findings of attenuated nitric oxide production in homogenates of platelets isolated from diabetic patients [16, 35] . In addition, our data show, for the first time, activation of platelet nitric oxide synthase by an increase of platelet free Ca 2+ concentration. We failed to obtain activation of nitric oxide synthase by ADP, a finding also reported previously [36] . In contrast to ADP, the Ca 2+ ATPase inhibitors thapsigargin (this study) and 2,5-di-(t-butyl)-1,4-benzohydroquinone (BHQ; [11] ) induce activation of nitric oxide synthase in human platelets. The difference between ADP and thapsigargin in terms of their properties to stimulate platelet nitric oxide synthase reported here are unclear and might be caused by thapsigargin having a greater effect on intracellular Ca 2+ concentration than ADP. Because of the reduced basal nitric oxide activity, thapsigarginstimulated nitric oxide activity was strongly reduced in platelets from diabetic patients, despite the increased Ca 2+ signalling occurring to this agonist in this group. In arteries of diabetic patients reduced endothelium-dependent relaxation was shown to improve by co-incubation with L-arginine [37, 38] . In platelets, L-arginine was essential for nitric oxide biosynthesis in both groups (data not shown), but there was no reduced L-arginine uptake in the platelets from diabetic patients which would explain the blunted nitric oxide synthase activity. In spite of these findings, there was evidence in alloxan diabetic rats of an increased arginase activity [39] which might result in a diversion of L-arginine to other end-points than NO.
It has been reported that the lack of cofactors essential for nitric oxide synthase activity (i. e. NAD-PH, tetrahydrobiopterine) might be responsible for an attenuation of endothelial dependent relation in diabetes [40] and hypercholesterolaemia [41] ; whether this lack of cofactor(s) is responsible for the reduced nitric oxide synthase activity in diabetes or not needs further investigation. Alternatively, diabetic conditions might already affect expression of nitric oxide synthase in the megacaryocytes, resulting in a reduced appearance of this enzyme in the platelets in diabetes.
Beside the reduced nitric oxide biosynthesis reported here, it might be expected that the increased production of superoxide anions favors the scavenging of nitric oxide by this type of oxygen radical, a phenomenon recently reported in endothelial cells under hyperglycaemic conditions [20] . Thus, in diabetes the concentration of nitric oxide is limited by its reduced biosynthesis and an enhanced degradation. This reduction of nitric oxide might put platelet cells in a more sensitive state, due to reduced pacemaker potential of the nitric oxide on platelet aggregation. Since nitric oxide attenuates platelet Ca 2+ signalling to ADP (this study), thrombin and 2,5-di-(t-butyl)-1,4-benzohydroquinone, another Ca 2+ ATPase inhibitor [11] , and therefore, constitutes an important negative feedback mechanism during platelet activation by autacoids, the reduced nitric oxide production (and enhanced nitric oxide degradation by superoxide anions) in platelets during diabetes might favor autacoid Ca 2+ signalling and, thus, aggregation. This hypothesis is further supported by our findings that the nitric oxide donor DEA/NO [27] , t = 2.1 min at 37°C and pH 7.4) normalized upregulated Ca 2+ signalling to ADP in platelets isolated from diabetic patients and after preincubation with the superoxide anion-generating system xanthine oxidase/hypoxanthine. These findings agree with a report which showed that the precursor of nitric oxide, L-arginine, inhibited increased platelet activity in alloxan diabetic rats [39] . Since L-arginine as well as nitric oxide are known to interact with superoxide anions [42] , however, it remains to be investigated whether or not the beneficial effect of L-arginine and nitric oxide to normalize platelet function and Ca 2+ signalling is due to scavenging properties or a direct effect on Ca 2+ signalling mechanisms.
We think that diabetes is accompanied with an increased release of superoxide anions in platelets, resulting in an increased intracellular Ca 2+ signalling to stimulation with autacoids. At the same time biosynthesis of nitric oxide, a compensatory mechanism to prevent hyperreactivity of platelets, is strongly attenuated in diabetes. Overall these phenomena might contribute to the enhanced platelet aggregation found in diabetic patients. Due to the potency of glutathione to normalize platelet Ca 2+ signalling in platelets from diabetic patients, this study might guide us to a therapeutic prevention against diabetes-mediated hyperreactivity of platelets and additional studies are urgently needed.
